Oncolytics Biotech presentated data from a single arm clinical study examining the use of Reolysin in combination with gemcitabine in patients with advanced pancreatic cancer ,data from a single arm clinical study examining the use of Reolysin in patients with primary glioblastomas or brain metastases, as well as preclinical data. Highlights of the data presented include clinical evidence that Reolysin treatment results in immunological changes to both the tumor cells and the tumor microenvironment that is conducive to novel immune targeting interventions; and pancreatic cancer patients receiving combination therapy with Reolysin and gemcitabine demonstrated a median overall survival of 10.2 months, and one- and two-year survival rates of 45% and 24%, respectively.